Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsOscar Health Amyloidosis Drug Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentOscar HealthPolicy CG109

    Agents for Amyloidosis-Associated Polyneuropathy - Medical Benefit Preferred Physician-Administered Drug Exceptions Criteria

    Customize your policy alerts

    Sign up for Oscar Health Policy CG109 alerts

    Get alerted when Policy CG109 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-benefit exception requests for physician-administered agents used to treat amyloidosis-associated polyneuropathy. It identifies preferred and non-preferred products and establishes when an exception to the preferred self-administered product may be approved.

    Policy Summary
    PayerOscar Health
    PolicyAgents for Amyloidosis-Associated Polyneuropathy - Medical Benefit Preferred Physician-Administered Drug Exceptions Criteria
    Policy CodePolicy CG109
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJan 1, 2026
    Next Review DateN/A
    Key ActionDocument a qualifying exception to preferred Wainua and submit supporting clinical documentation before requesting a physician-administered anti-transthyretin siRNA agent.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Products listed in the Medical Preferred Drug List
    1Preferred physician-administered product
    1Non-preferred physician-administered product
    Up to 12 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Standard authorization period
    3 monthsShortage-based authorization period
    2Applicable billing codes

    Coverage Criteria

    Physician-administered anti-transthyretin siRNA exception

    Coverage for a physician-administered anti-transthyretin siRNA agent is provided when ALL of the following are met.

    Required exception criteria

    • Qualifying exception to Wainua: Documentation supports at least ONE of the following circumstances: trial and failure or inadequate response despite an appropriate duration of Wainua therapy; an intolerable adverse event preventing continued use; hypersensitivity to specific excipients precluding use of all preferred products; a contraindication to Wainua that would not exist or be reasonably expected to occur with the requested non-preferred product; Wainua has not received the requested FDA approval, is not supported by evidence-based guidelines, or is not clinically appropriate for the member’s diagnosis; or Wainua shortage or unavailability.
    • Supporting documentation: Clinical documentation is provided to support the exception request.

      Documentation may include Wainua trial dates, doses, and duration; the nature and severity of inadequate response, adverse reactions, or contraindications; relevant laboratory results and clinical notes; specialist consultation notes; or notification of drug shortage or unavailability.

    Experimental, investigational, or medically unnecessary use

    Products are not covered when used for experimental, investigational, or medically unnecessary indications.

    Non-covered use: Use is outside FDA-approved labeling or is not supported by current medical evidence and standards of care, including a clinically inappropriate indication based on age, dosing, frequency, duration of therapy, site of administration, or contraindication; non-FDA-approved or off-label use without sufficient evidence supporting safety and efficacy; doses exceeding the FDA-approved label or clinical practice guidelines without sufficient evidence supporting safety and efficacy; use not required to treat or manage the member’s medical condition; use not aligned with generally accepted medical practice; or use primarily for the convenience of the member, family, or provider.

    The Plan does not cover non-FDA-approved indications or off-label use unless sufficient evidence supports safety and efficacy. Doses exceeding the FDA-approved label or clinical practice guidelines are also not covered without sufficient evidence supporting safety and efficacy.

    Use is considered not medically necessary when it is not clinically appropriate based on the indication, including the member’s age, dosage, frequency, duration of therapy, site of administration, or contraindications. Coverage is also excluded when the product is not required to treat or manage the member’s condition, is inconsistent with generally accepted medical practice, or is used primarily for the convenience of the member, family, or provider.

    Initial Therapy Criteria

    Initial physician-administered product exception

    For all physician-administered anti-transthyretin siRNA agents in Table 1, initial approval requires ALL of the following:

    Initial exception approval

    • Qualifying basis for not using Wainua: At least ONE of the following is documented: trial and failure or inadequate response despite an appropriate duration of therapy; an intolerable adverse event preventing continued use; hypersensitivity to specific excipients precluding all preferred products; a qualifying contraindication to Wainua; lack of requested FDA approval, evidence-based guideline support, or clinical appropriateness for the member’s diagnosis; or Wainua shortage or unavailability.
    • Clinical documentation is provided to support the exception request.

    Continuation During Shortage or Unavailability

    Continuation during shortage or unavailability

    When approval is based on drug shortage or unavailability:

    Shortage-based continuation: Continued documentation of Wainua (eplontersen) shortage or unavailability is provided.

    Initial approval is for 3 months and may be extended based on continued documentation. If the shortage or unavailability resolves before the authorization period ends, the Plan may require transition to the preferred product at the next authorization period.

    Preferred Product Sequencing

    StepPreferred therapyRequirement before requesting a physician-administered agent
    1Wainua (eplontersen), self-administeredTry Wainua first. An exception may be considered when there is documented trial failure or inadequate response after an appropriate duration, an intolerable adverse event, hypersensitivity to specific excipients, a qualifying contraindication, lack of requested FDA approval or evidence-based guideline support, lack of clinical appropriateness, or drug shortage or unavailability.

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization and Preferred-Drug Exception Required

    Prior authorization is required for physician-administered anti-transthyretin siRNA agents used to treat amyloidosis-associated polyneuropathy. The requested product may be authorized for up to 12 months when all exception criteria are met.

    • Submit the request under the Medical Benefit Preferred Drug Exceptions Criteria.
    • The criteria apply to all agents for amyloidosis-associated polyneuropathy listed in the policy's Table 1.
    Step Therapy

    Document Failure or Inability to Use Wainua

    Document that the member has tried and failed, had an inadequate response or intolerance to, or has a contraindication to preferred self-administered Wainua (eplontersen), or document why Wainua cannot be used.

    • Provide a trial and failure or inadequate response despite an appropriate duration of therapy.

    Covered CPT and HCPCS Codes

    CPT/HCPCS Codes considered medically necessary if criteria are metHCPCSCovered
    J0225Amvuttra Injection, vutrisiran, 1 mg
    J0222Onpattro Injection, patisiran, 0.1 mg

    Policy Background

    This policy addresses physician-administered anti-transthyretin small interfering RNA (siRNA) agents for amyloidosis-associated polyneuropathy. The Medical Preferred Drug List promotes cost-effective and clinically appropriate physician-administered specialty drugs, while allowing an exception when the preferred self-administered agent cannot be used. Coverage remains subject to FDA labeling, current medical evidence, accepted standards of care, and the member’s plan terms.

    Policy Definitions

    Definitions
    TermCompendia
    DefinitionSummaries of drug information and medical evidence used to support decision-making about the appropriate use of drugs and medical procedures.
    ExamplesAmerican Hospital Formulary Service Drug Information; Elsevier Clinical Pharmacology; National Comprehensive Cancer Network Drugs and Biologics Compendium; Thomson Micromedex DrugDex; and United States Pharmacopeia-National Formulary (USP-NF).
    Definitions
    TermContraindication
    DefinitionA pre-existing condition or factor that precludes use of a drug due to risk of harm.
    Policy Summary
    PayerOscar Health
    PolicyAgents for Amyloidosis-Associated Polyneuropathy - Medical Benefit Preferred Physician-Administered Drug Exceptions Criteria
    Policy CodePolicy CG109
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJan 1, 2026
    Next Review DateN/A
    Key ActionDocument a qualifying exception to preferred Wainua and submit supporting clinical documentation before requesting a physician-administered anti-transthyretin siRNA agent.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation During Shortage or UnavailabilityPreferred Product SequencingAuthorization and Documentation RequirementsCovered CPT and HCPCS CodesPolicy BackgroundPolicy Definitions
  1. Document an intolerable adverse event, hypersensitivity to specific excipients, or a contraindication that would not exist or reasonably be expected with the requested product.
  2. Explain when Wainua lacks the requested FDA approval, is not supported by evidence-based guidelines, or is not clinically appropriate for the member's diagnosis.
  3. A drug shortage or unavailability of Wainua may also support the exception request.
  4. Documentation Required

    Exception Request Documentation Required

    Provide clinical documentation supporting the preferred-product exception and the medical necessity of the requested physician-administered agent.

    • Include specific details of the Wainua trial, including dates, doses, and duration.
    • Describe the nature and severity of inadequate response, adverse reactions, or contraindications.
    • Include relevant laboratory results and clinical notes supporting treatment failure.
    • Include specialist consultation notes supporting the need for a physician-administered anti-transthyretin siRNA agent.
    • For a shortage or unavailability exception, include notification or other documentation of the shortage or unavailability.
    Documentation Required

    Supporting Medical Records

    Submit supporting medical records sufficient to establish the diagnosis, prior treatment history, and the basis for the requested exception.

    • Provide up-to-date chart notes, relevant test results, and/or imaging reports supporting the diagnosis.
    • Provide prescription claims records and/or prescription receipts supporting prior trials of alternatives.
    • Include clinical notes and laboratory results documenting treatment failure, inadequate response, adverse effects, intolerance, or contraindication.
    Denial Risk

    Failure to Meet Criteria May Result in Denial

    The request may be denied when the member does not meet the preferred-product exception criteria or when the requested use is experimental, investigational, or not medically necessary.

    • Denial may result when failure, inadequate response, intolerance, contraindication, or inability to use Wainua is not adequately established.
    • Denial may result when required clinical documentation is missing or insufficient.
    • Coverage is not provided for non-FDA-approved or unsupported off-label use, excessive dosing without sufficient evidence, uses not required to treat or manage the condition, uses inconsistent with generally accepted medical practice, or use primarily for convenience.
    Billing Rule

    Transition After Shortage Resolution

    When the exception is based on a drug shortage or unavailability of Wainua, the initial authorization is limited to 3 months and may be extended only with continued documentation that the shortage or unavailability persists.

    • If the shortage or unavailability resolves before the authorization period ends, the Plan may require transition to preferred Wainua at the next authorization period.
    Coverage relevance
    A contraindication may prevent use of the affected drug.
    Definitions
    TermDocumentation
    DefinitionWritten information supporting diagnoses and prior trials of alternatives.
    ExamplesUp-to-date chart notes, relevant test results or imaging reports, prescription claims records, and prescription receipts.
    Definitions
    TermExperimental or Investigational
    DefinitionA procedure, drug, or device that has not been proven effective or has not been approved by the appropriate regulatory bodies.
    Applies toProcedures, drugs, and devices.
    Definitions
    AbbreviationFDA
    Full nameFederal Food and Drug Administration.
    Policy contextThe FDA is an appropriate regulatory body for approval of procedures, drugs, or devices.
    Definitions
    TermIntolerance
    DefinitionThe inability to tolerate or endure a medication or treatment because of subjectively difficult or harmful side effects, reactions, or hypersensitivities.
    Treatment impactThe effects negatively impact quality of life, ability to adhere, or overall health; documentation should detail the specific intolerable effects and their impact on treatment.
    Definitions
    TermMedical Benefit Preferred Drug Exceptions Criteria
    DefinitionPlan requirements that must be met for a drug to be approved for coverage.
    Example requirementTrial and failure of preferred drugs first.